Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy

S.A. Blankenstein, M.J.B. Aarts, F.W.P.J. van den Berkmortel, M.J. Boers-Sonderen, A.J.M. van den Eertwegh, M.G. Franken, J.W.B. de Groot, J.B.A.G. Haanen, G.A.P. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, M.W.J.M. Wouters, A.C.J. van Akkooi*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)
Original languageEnglish
Article number1176
Number of pages14
JournalCancers
Volume12
Issue number5
DOIs
Publication statusPublished - 1 May 2020

Keywords

  • braf
  • combined nivolumab
  • dabrafenib
  • double-blind
  • dutch melanoma treatment registry
  • ipilimumab
  • metastatic melanoma
  • multicenter
  • open-label
  • phase-3
  • surgery
  • survival
  • systemic therapy
  • SURVIVAL
  • DABRAFENIB
  • MULTICENTER
  • COMBINED NIVOLUMAB
  • OPEN-LABEL
  • BRAF
  • PHASE-3
  • METASTATIC MELANOMA
  • DOUBLE-BLIND
  • Dutch Melanoma Treatment Registry
  • IPILIMUMAB

Cite this